Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05301062 | A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well…(CREDIT) | — | terminated | Mar 29, 2022 | Bayer | Due to the changes of standard of care, the slow recruitment of participants, and the similar… | Safety / toxicity |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 25, 2010 | University of Nebraska | study sponsors withdrew support for the study drug. | Other (stated, no rule matched) |
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in… | Phase 2 | terminated | Nov 9, 2018 | Nabil Adra | Lack of accrual | Enrollment / accrual |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | Phase 2 | withdrawn | Jan 4, 2022 | Bradley A. McGregor, MD | The overall protocol will be changed in a new amendment, which will be resubmitted under the new… | Other (stated, no rule matched) |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic…(CHARTER) | — | terminated | Jun 29, 2022 | Angle plc | Futility (slow enrollment) | Efficacy / futility |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT03606174 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens… | Phase 2 | terminated | Jul 30, 2018 | Mirati Therapeutics Inc. | The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety… | Safety / toxicity |
| NCT04271254 | PET/MR Characterization of Renal Cell Carcinomas | N/A | terminated | Feb 17, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding insufficiency. | Funding |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Jan 13, 2020 | Tceleron Therapeutics, Inc. | Based on the safety events and evidence of biologic activity without sustained clinical responses… | Safety / toxicity |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Aug 5, 2022 | Tceleron Therapeutics, Inc. | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | Phase 1 | terminated | Oct 5, 2020 | Novo Nordisk A/S | Sponsor Decision | Sponsor / business decision |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A… | N/A | terminated | Aug 31, 2009 | Cantonal Hospital of St. Gallen | poor patient accrual | Enrollment / accrual |
| NCT04398368 | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in… | Phase 2 | terminated | May 21, 2020 | Mayo Clinic | Focus research efforts on other projects. | Other (stated, no rule matched) |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma…(IMmotion010) | Phase 3 | terminated | Jan 19, 2017 | Hoffmann-La Roche | The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted… | Sponsor / business decision |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | Phase 1 | withdrawn | Jun 12, 2018 | University of Southern California | Budget issues | Funding |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | Phase 2 | terminated | Jan 12, 2018 | pharmaand GmbH | Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment. | Efficacy / futility |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate… | Phase 2 | terminated | Aug 6, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | insufficient clinical response per DSMB | Other (stated, no rule matched) |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined…(THRIP) | N/A | terminated | Jun 12, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | outdated, progress in clinical practice. | Other (stated, no rule matched) |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase 3 | terminated | May 24, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by DSMB due to futility. | Efficacy / futility |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | Phase 1 / Phase 2 | terminated | Apr 13, 2021 | Veru Inc. | Study terminated as end points were not achieved at current dose level. | Other (stated, no rule matched) |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell… | Phase 2 | withdrawn | Oct 26, 2020 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Sep 4, 2019 | Calibr, a division of Scripps Research | Business decision | Sponsor / business decision |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent… | Phase 2 | withdrawn | Feb 21, 2023 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Program changed | Other (stated, no rule matched) |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | Phase 1 | withdrawn | May 10, 2021 | Syneos Health | Study abandoned, no participants enrolled | Enrollment / accrual |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | Phase 2 | withdrawn | Nov 4, 2021 | 4D pharma plc | Sponsor unable to proceed | Other (stated, no rule matched) |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma… | Phase 2 | withdrawn | Aug 11, 2022 | Bristol-Myers Squibb | Replaced it with another clinical trial | Other (stated, no rule matched) |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate…(CROSSBOW) | Phase 2 | terminated | Sep 11, 2019 | Sir Mortimer B. Davis - Jewish General Hospital | Drug no longer available | Other (stated, no rule matched) |
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared… | Phase 3 | terminated | Nov 2, 2018 | Nektar Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT05221827 | Clinical Performance Evaluation of the C2i-Test | — | terminated | Feb 3, 2022 | C2i Genomics | Not in line with company's recently updated clinical development strategy | Sponsor / business decision |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | Phase 1 | terminated | Aug 29, 2017 | Advaxis, Inc. | Business decision | Sponsor / business decision |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | Phase 3 | terminated | Feb 24, 2023 | Timothy Hoffman | The investigational product was approved by the FDA (12/20/2021) and is now commercially available | Other (stated, no rule matched) |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | — | terminated | Jan 13, 2016 | CENTOGENE GmbH Rostock | Study no longer pursued. | Other (stated, no rule matched) |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Phase 2 | terminated | Mar 29, 2016 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate…(PRIMA) | Phase 2 | terminated | Apr 20, 2015 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03671304 | Mobile Intervention - Physical Activity in Cancer Treatment | N/A | terminated | Sep 14, 2018 | University of Texas Southwestern Medical Center | The study was prematurely discontinued, the application utilized with the fitbit is no longer being… | Other (stated, no rule matched) |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 26, 2023source: clinicaltrials